Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
The collaboration brings a seamless digital experience to more formulators worldwide
Subscribe To Our Newsletter & Stay Updated
